Vidal M - Search Results

1

[¹⁸F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to ¹⁸F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases.

Rizzo-Padoin N, Chaussard M, Vignal N, Kotula E, Tsoupko-Sitnikov V, Vaz S, Hontonnou F, Liu WQ, Poyet JL, Vidal M, Merlet P, Hosten B, Sarda-Mantel L. Rizzo-Padoin N, et al. Among authors: vidal m. Nucl Med Biol. 2016 Dec;43(12):773-780. doi: 10.1016/j.nucmedbio.2016.08.010. Epub 2016 Aug 24. Nucl Med Biol. 2016. PMID: 27693672

2

Inhibition of the ras-dependent mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties.

Liu WQ, Vidal M, Mathé C, Périgaud C, Garbay C. Liu WQ, et al. Among authors: vidal m. Bioorg Med Chem Lett. 2000 Apr 3;10(7):669-72. doi: 10.1016/s0960-894x(00)00077-9. Bioorg Med Chem Lett. 2000. PMID: 10762050

3

Inhibitors of Ras signal transduction as antitumor agents.

Garbay C, Liu WQ, Vidal M, Roques BP. Garbay C, et al. Among authors: vidal m. Biochem Pharmacol. 2000 Oct 15;60(8):1165-9. doi: 10.1016/s0006-2952(00)00428-7. Biochem Pharmacol. 2000. PMID: 11007954 Review.

4

Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.

Nioche P, Liu WQ, Broutin I, Charbonnier F, Latreille MT, Vidal M, Roques B, Garbay C, Ducruix A. Nioche P, et al. Among authors: vidal m. J Mol Biol. 2002 Feb 1;315(5):1167-77. doi: 10.1006/jmbi.2001.5299. J Mol Biol. 2002. PMID: 11827484

5

Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement.

Saci A, Liu WQ, Vidal M, Garbay C, Rendu F, Bachelot-Loza C. Saci A, et al. Among authors: vidal m. Biochem J. 2002 May 1;363(Pt 3):717-25. doi: 10.1042/0264-6021:3630717. Biochem J. 2002. PMID: 11964172 Free PMC article.

6

Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel.

Gril B, Vidal M, Assayag F, Poupon MF, Liu WQ, Garbay C. Gril B, et al. Among authors: vidal m. Int J Cancer. 2007 Jul 15;121(2):407-15. doi: 10.1002/ijc.22674. Int J Cancer. 2007. PMID: 17372910 Free PMC article.

7

The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.

Ye YB, Lin JY, Chen Q, Liu F, Chen HJ, Li JY, Liu WQ, Garbay C, Vidal M. Ye YB, et al. Among authors: vidal m. Biochem Pharmacol. 2008 Jun 1;75(11):2080-91. doi: 10.1016/j.bcp.2007.12.021. Epub 2008 Mar 22. Biochem Pharmacol. 2008. PMID: 18455151

8

Design and synthesis of C-terminal modified cyclic peptides as VEGFR1 antagonists.

Wang L, Gagey-Eilstein N, Broussy S, Reille-Seroussi M, Huguenot F, Vidal M, Liu WQ. Wang L, et al. Among authors: vidal m. Molecules. 2014 Sep 26;19(10):15391-407. doi: 10.3390/molecules191015391. Molecules. 2014. PMID: 25264829 Free PMC article.

9

Identification of Peptidic Antagonists of Vascular Endothelial Growth Factor Receptor 1 by Scanning the Binding Epitopes of Its Ligands.

Wang L, Zhou L, Reille-Seroussi M, Gagey-Eilstein N, Broussy S, Zhang T, Ji L, Vidal M, Liu WQ. Wang L, et al. Among authors: vidal m. J Med Chem. 2017 Aug 10;60(15):6598-6606. doi: 10.1021/acs.jmedchem.7b00283. Epub 2017 Jul 21. J Med Chem. 2017. PMID: 28686443

10

Synthesis and characterization of water-soluble macrocyclic peptides stabilizing protein α-turn.

Wang L, Coric P, Zhu K, Liu WQ, Vidal M, Bouaziz S, Broussy S. Wang L, et al. Among authors: vidal m. Org Biomol Chem. 2018 Jan 17;16(3):459-471. doi: 10.1039/c7ob02852k. Org Biomol Chem. 2018. PMID: 29265149

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,935 results

Search Page